Want to see CRMD full AI Analyst Report?
CRMD Stock Chart & Stats
$7.39
$0.06(0.58%)
At close: 4:00 PM EST
$7.39
$0.06(0.58%)
Day’s Range― - ―
52-Week Range$6.13 - $14.96
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.36M
Market Cap
$659.00M
Enterprise Value$646.98M
Total Cash (Recent Filing)$178.09M
Total Debt (Recent Filing)$147.41M
Price to Earnings (P/E)3.5
Beta1.68
Next Earnings
Aug 06, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.38
Shares Outstanding78,451,890
10 Day Avg. Volume943,001
30 Day Avg. Volume1,357,142
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.07
Price to Sales (P/S)2.69
P/FCF Ratio4.85
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit1.88
Enterprise Value/Ebitda3.04
Forecast
1Y Price Target
$14.00Price Target Upside89.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.5
Revenue Forecast (FY)$334.09M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & ProfitabilityThe company converted near-term earnings into cash at roughly 1.0x, generating ~ $197M FCF TTM and large operating cash flows. Durable cash conversion supports reinvestment, buybacks and debt service over the next 2–6 months, improving financial flexibility if margins hold.
DefenCath Commercial TractionSustained uptake by major dialysis providers and rising utilization indicate entrenched prescribing and protocol adoption. Durable commercial adoption by large customers reduces sales variability and supports recurring, predictable product volumes and revenue over the medium term.
REZZAYO Phase III Success & Regulatory PathPositive Phase III topline with planned sNDA and 2027 launch creates a durable pipeline option into the hospital antifungal market. Successful trial and regulatory path materially diversify product mix and provide a credible medium-term revenue growth vector beyond DefenCath sales.
Bears Say
TDAPA Expiration / Reimbursement RiskA CMS reimbursement transition can cause durable volume or price disruption for DefenCath in H2 2026. Even with stable utilization, lower or delayed add-on payments can materially reduce net selling price and cash receipts, pressuring margins and short-term cash flow until new payments stabilize.
Higher Leverage Vs Prior YearsThe recent step-up in debt increases financial sensitivity to any earnings reversion. While leverage is moderate today, higher debt reduces cushion versus prior cash-consuming periods and limits optionality for capex, M&A, or further buybacks if margins decline.
Prior Operational Volatility & Pre-2025 LossesA dramatic recent profitability inflection follows several years of losses and negative cash flow. That historical volatility raises the risk the current margin and cash conversion rates may not persist, meaning medium-term forecasts should account for potential regression toward prior cash-consumptive patterns.
Cormedix News
CRMD FAQ
What was Cormedix Inc.’s price range in the past 12 months?
Cormedix Inc. lowest stock price was $6.13 and its highest was $14.96 in the past 12 months.
What is Cormedix Inc.’s market cap?
Cormedix Inc.’s market cap is $659.00M.
When is Cormedix Inc.’s upcoming earnings report date?
Cormedix Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 23 days.
How were Cormedix Inc.’s earnings last quarter?
Cormedix Inc. released its earnings results on May 14, 2026. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.343 by $0.087.
Is Cormedix Inc. overvalued?
According to Wall Street analysts Cormedix Inc.’s price is currently Undervalued.
Does Cormedix Inc. pay dividends?
Cormedix Inc. does not currently pay dividends.
What is Cormedix Inc.’s EPS estimate?
Cormedix Inc.’s EPS estimate is 0.24.
How many shares outstanding does Cormedix Inc. have?
Cormedix Inc. has 78,451,890 shares outstanding.
What happened to Cormedix Inc.’s price movement after its last earnings report?
Cormedix Inc. reported an EPS of $0.43 in its last earnings report, beating expectations of $0.343. Following the earnings report the stock price went up 5.733%.
Which hedge fund is a major shareholder of Cormedix Inc.?
Currently, no hedge funds are holding shares in CRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cormedix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (89.45% Upside)
$14.00 (89.45% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 327.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.26%
12-Months-Change
Fundamentals
Return on Equity
50.38%
Trailing 12-Months
Asset Growth
445.27%
Trailing 12-Months
Company Description
Cormedix Inc.
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
CRMD Stock 12 Month Forecast
Average Price Target
$14.00
▲(89.45% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.91% Insiders
10.20% Mutual Funds
0.78% Other Institutional Investors
72.78% Public Companies and
Individual Investors